Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review

This study got the wrong result: "The rate of AKI was higher in the Actemra group than the control group, OR=1.83, but in-hospital mortality was lower, HR=0.63" https://t.co/imTMsJlJj7 https://t.co/TIFZK67Tqr https://t.co/Ys2ItluDYO https://t.co/tUMLjEdSQ0

7-6-23: Guizhou, China: The organ transplant anti-rejection drug, Actemra (tocilizumab): https://t.co/XWyhfM2sdu https://t.co/imTMsJlJj7 https://t.co/wLO97St5A7 https://t.co/CuN0EIKimu https://t.co/uXtjYWYzJa https://t.co/7xM0ubIKTP https://t.co/lDM2yYgfUC

Actemra prevents organ transplant deaths https://t.co/lDM2yYfI54 https://t.co/7xM0ubId4h https://t.co/XWyhfM1UnW https://t.co/RT8Gv8TV1u https://t.co/CuN0EIJKwW https://t.co/imTMsJlbtz https://t.co/wLO97SsxKz https://t.co/ngnnDY8Tnb https://t.co/nmLRBrRfsV

12-1-2022: West Hollywood, California: The organ transplant anti-rejection drug, Actemra (tocilizumab), was called in to combat both the oxidative stress and the cytokine attack of the endothelium of kidney transplant patients: https://t.co/imTMsJlbtz htt